Today: 12 November 2025
Subscribe
Browse Tag

Pfizer

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs (maximum $86.25 per share). The structure, which Metsera’s board deemed superior on value and certainty of closing, is expected to go to a shareholder vote on Nov. 13 before closing. Reuters+1 While Novo Nordisk pushed the bidding to similar headline value, meticulous antitrust calculus tipped the field. Reuters Breakingviews reports that FTC outreach helped steer Metsera toward Pfizer; coupled with
11 November 2025
 ·  ·  ·  ·  ·  ·  · 
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure. Key takeaways (Nov. 10) What changed today The revised terms, line by line (from today’s 8‑K) Metsera’s Form 8‑K filed this morning lays out material changes versus the September agreement: Why Novo bowed out — and the FTC’s
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing
8 November 2025
 ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways What happened (Nov. 7–8) Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1 Notably, Pfizer had already received early termination of the HSR waiting period from
8 November 2025
 ·  ·  ·  · 
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Key takeaways What happened today Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the
8 November 2025
 ·  ·  ·  ·  ·  · 
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. What happened today Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued at up to $10 billion. Metsera’s board cited legal and regulatory certainty in favoring Pfizer’s revised terms, while Novo Nordisk said it will not raise its competing proposal and is exiting the race. The merger is expected to close shortly
8 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Last updated: Nov 7, 2025 (19:23 UTC) Pfizer (NYSE: PFE) shares were trading around $24.28, down roughly 2.3% intraday, as investors weighed new twists in the Metsera takeover fight and marked today’s dividend record date. As of the latest print, the stock’s day range was $24.12–$24.61 on heavy volume. Key takeaways Pfizer stock price today (intraday) What changed today — Nov 7, 2025 1) Metsera bidding war heats up Why it matters: The Metsera outcome could reshape Pfizer’s cardiometabolic/obesity ambitions after earlier setbacks, and investors are repricing PFE daily on any signal of who ultimately wins—and at what cost. Financial
7 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

Key takeaways What happened today (Nov. 6) 1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1 2) Pfizer signals a sweeter counter—because the clock is tight.Reporting overnight indicates Pfizer plans to sweeten
6 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20s reuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billion stockanalysis.com – substantially smaller than several years ago
5 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera Stock Overview and Recent Performance Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alone reuters.com reuters.com. The share price is now hovering in the low $70s reuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emerged prnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4 reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Detailed Analysis and Outlook Stock Price Trends and Technical Analysis Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week range ($20.92 – $28.00) marketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s (a ~10% jump) following its government pricing deal announcement marketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However,
4 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share reuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performance reuters.com reuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal” reuters.com. This was weeks
4 November 2025
 ·  ·  ·  ·  ·  · 
1 2 3
Go toTop